Tiziana Life Sciences plc ("Tiziana" or the "Company") - AIM Delisting and Admission to the Standard Listing Segment of Main Market
Tiziana Life Sciences has announced its transition from AIM to the Main Market of the London Stock Exchange, effective January 21, 2021. Following the last trading day on AIM on January 20, the Company’s Ordinary Shares will be admitted to the Official List and commence trading on the Main Market. Tiziana focuses on developing innovative treatments for oncology, inflammation, and infectious diseases, with ongoing Phase 2 studies for its uniquely human anti-CD3 monoclonal antibody, Foralumab, targeting conditions such as Crohn's Disease and multiple sclerosis.
- Transitioning to the Main Market of the London Stock Exchange enhances visibility and accessibility for investors.
- Ongoing Phase 2 studies for Foralumab may lead to significant advancements in treatment for autoimmune diseases.
- None.
NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM and admission to listing of its ordinary shares (the "Ordinary Shares") on the standard listing segment of the Official List of the Financial Conduct Authority ("FCA") (the "Official List") and admission to trading on the main market for listed securities (the "Main Market") of London Stock Exchange plc (the "London Stock Exchange") (together, "Admission").
As previously announced, the last day of trading of the Company's Ordinary Shares on AIM will be today, 20 January 2021 and the AIM Delisting will be effective from 7.00 am 21 January 2021. Admission of shares to the Official List and commencement of dealing in the Ordinary Shares of the Company on the Main Market will be effective from 8.00 am on 21 January 2021.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating Phase 2 studies with orally administered Foralumab for Crohn’s Disease and nasally administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
| For further enquiries: United Kingdom: Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder | +44 (0)20 7495 2379 |
| United States: Investors: Dave Gentry, CEO RedChip Companies Inc. 407-491-4498 dave@redchip.com |
FAQ
What is the latest update for Tiziana Life Sciences (TLSA) regarding its stock listing?
When will Tiziana Life Sciences (TLSA) stop trading on AIM?
What are the therapeutic focuses of Tiziana Life Sciences (TLSA)?
What is Foralumab and its significance for Tiziana Life Sciences (TLSA)?
